Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest

Chie Nagata, Satoshi Yanagida, Aikou Okamoto, Asuka Morikawa, Kohei Sugimoto, Shigehisa Okamoto, Kazunori Ochiai, Tadao Tanaka
Journal of Obstetrics and Gynaecology Research · 2012 · vol. 38(4) , pp. 639–644 · doi:10.1111/j.1447-0756.2011.01778.x · PMID:22413833 · W1894602830
article OA: closed CC0 ⤵ 30 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

Younger age, pre-treatment anemia, and elevated estradiol after three months of treatment are risk factors for adenomyosis patients discontinuing dienogest due to uterine bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Adenomyosis patients treated with dienogest are considered to be at higher risk of uterine bleeding; however, the mechanisms which cause severe uterine bleeding in those patients are unknown. This study aims to investigate the risk factors of uterine bleeding among adenomyosis patients treated with dienogest. MATERIAL AND METHODS: Clinical data of 51 adenomyosis patients treated with dienogest were retrospectively collected from their medical records. The impact of potential risk factors (age, sagittal square area of the uterus before treatment, and estradiol at the third month of treatment) and confounders (hemoglobin before treatment and prior medical treatments) on the time to treatment discontinuation due to uterine bleeding was assessed using log-rank tests and a Cox proportional hazard model. RESULTS: Age (< 38 years, P = 0.004), hemoglobin before treatment (<12 g/dL, P = 0.047), and estradiol at the third month of treatment (≥ 60 pg/mL, P = 0.027) had statistically significant effects on the time to treatment discontinuation due to uterine bleeding. Age was still statistically significant after controlling for hemoglobin (P = 0.023). CONCLUSION: Adenomyosis patients treated with dienogest are at higher risk of treatment discontinuation due to uterine bleeding, especially when they are of younger age, have anemia before treatment, and/or have mildly suppressed or unsuppressed estradiol after they started dienogest treatment. Clinicians should pay special attention when they prescribe dienogest for such patients.

My notes (saved in your browser only)

Condition tags

mesh:D004715adenomyosis

MeSH descriptors

Endometriosis Nandrolone Uterine Hemorrhage Adult Endometriosis Female Hemoglobins Hemoglobins Humans Middle Aged Nandrolone Nandrolone Proportional Hazards Models Retrospective Studies Risk Factors Uterine Hemorrhage

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (30)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:17.081435+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK